Gilead Sciences, Inc. $GILD Stock: State Street Corp Decreases Stake

State Street Corp lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 60,954,967 shares of the biopharmaceutical company’s stock after selling 261,585 shares during the period. State Street Corp’s holdings in Gilead Sciences were worth $9,085,338,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in GILD. Intesa Sanpaolo Wealth Management boosted its stake in Gilead Sciences by 1.9% during the third quarter. Intesa Sanpaolo Wealth Management now owns 8,891 shares of the biopharmaceutical company’s stock worth $1,325,000 after acquiring an additional 165 shares in the last quarter. Cornerstone Select Advisors LLC increased its stake in shares of Gilead Sciences by 5.4% during the third quarter. Cornerstone Select Advisors LLC now owns 19,759 shares of the biopharmaceutical company’s stock valued at $2,945,000 after purchasing an additional 1,015 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. increased its stake in shares of Gilead Sciences by 55.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 10,996 shares of the biopharmaceutical company’s stock valued at $1,639,000 after purchasing an additional 3,904 shares in the last quarter. Sumitomo Life Insurance Co. increased its stake in shares of Gilead Sciences by 1.2% during the third quarter. Sumitomo Life Insurance Co. now owns 15,501 shares of the biopharmaceutical company’s stock valued at $2,310,000 after purchasing an additional 188 shares in the last quarter. Finally, Saranac Partners Ltd bought a new position in shares of Gilead Sciences during the third quarter valued at approximately $405,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on GILD. Barclays lifted their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the company an “equal weight” rating in a report on Monday, November 16th. Cantor Fitzgerald upped their price target on Gilead Sciences from $155.00 to $175.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. UBS Group raised their price objective on Gilead Sciences from $175.00 to $195.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Needham & Company LLC set a $175.00 price objective on Gilead Sciences in a research report on Friday, October 30th. Finally, Royal Bank Of Canada lifted their price objective on Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a research note on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $171.63.

Check Out Our Latest Stock Analysis on Gilead Sciences

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $171.47, for a total value of $514,410.00. Following the completion of the transaction, the chief financial officer directly owned 158,096 shares in the company, valued at $27,108,721.12. The trade was a 1.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Wettan Keeley M. Cain sold 3,399 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $164.11, for a total value of $557,809.89. Following the completion of the transaction, the executive vice president directly owned 5,360 shares in the company, valued at $879,629.60. This trade represents a 38.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 237,709 shares of company stock worth $39,799,137. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $166.33 on Friday. Gilead Sciences, Inc. has a 1 year low of $116.88 and a 1 year high of $176.58. The firm’s 50-day moving average is $157.26 and its 200 day moving average is $142.46. The stock has a market cap of $206.30 billion, a price-to-earnings ratio of -52.64 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. The business had revenue of $8.30 billion during the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. Gilead Sciences’s revenue was up 6.8% compared to the same quarter last year. During the same period last year, the business earned $2.47 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.97 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. Gilead Sciences’s dividend payout ratio is presently -103.80%.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Recommended Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.